PartnershipAug 3, 2026, 08:02 AM
Taysha Gene Therapies, Catalent Sign Commercial Supply Agreement
AI Summary
Taysha Gene Therapies, Inc. and Catalent, Inc. have announced a commercial supply agreement for TSHA-102, Taysha's investigational gene therapy for Rett syndrome. Under the agreement, Catalent will be the primary commercial manufacturer for TSHA-102 following potential FDA approval. This partnership secures long-term manufacturing capacity and a scalable supply framework, strengthening Taysha's commercial infrastructure and launch readiness for TSHA-102.
Key Highlights
- Taysha Gene Therapies and Catalent announced a commercial supply agreement for TSHA-102.
- Catalent will serve as Taysha's primary commercial manufacturer for TSHA-102.
- The agreement secures long-term commercial manufacturing capacity and scalable supply.
- Catalent will provide GMP manufacturing at its FDA-licensed facility in Harmans, Maryland.
- The partnership builds on an existing relationship that began in 2020.
- TSHA-102 is Taysha's investigational gene therapy in pivotal development for Rett syndrome.
Price Impact
More from TSHA